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Summary Abdominal obesity is a principal risk factor in the development of metabolic
syndrome. Previously, we showed that a palatinose-based liquid formula, Inslow/MHN-01,
suppressed postprandial plasma glucose level and reduced visceral fat accumulation better
than the standard formula (SF). To elucidate the mechanism of Inslow-mediated anti-obesity
effect, expression levels of genes involved in the glucose and lipid metabolism were compared
in Inslow- and SF-fed rats. Both fasting plasma insulin level and average islet sizes were
reduced in the Inslow group. We also found less abdominal fat accumulation and reduced
hepatic triacylglycerol content in the Inslow group. Expression of the β-oxidation enzymes and
uncoupling potein-2 (UCP-2) mRNAs in the liver of the Inslow group were higher than the SF
group, which was due to a concomitant higher expression of the peroxisome proliferator-
activated receptor (PPAR)-α mRNA in the former. Furthermore, expression of the UCP-2 and
adiponectin mRNAs in the epididymal fat were higher in the Inslow group than the SF group,
and were stimulated by a concomitant increase of the PPAR-γ gene expression in the former.
These results strongly suggested that the anti-obesity effect of Inslow was due to an increase
in the hepatic PPAR-α and adipocyte PPAR-γ gene expressions.
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Introduction
Metabolic syndrome, characterized by hyperglycemia
and dyslipidemia, is increasingly becoming prevalent in
industrialized countries [1, 2]. Obesity is the principal risk
factor of metabolic syndrome, and is developed when the en-
ergy intake exceeds the energy expenditure [3, 4]. In particular,
high fat diets induces hyperglycemia and hyperinsulinemia
due to pancreas overworking and/or dysfunction, and increases
fat storage in the liver and adipose tissue. Consequently, the
vicious cycle of the insulin resistance is enhanced.
It is well known that liver and adipose tissues play
important roles in lipid and glucose homeostasis. Peroxisomal
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proliferator-activated receptor (PPAR)-α has a role in fatty
acid catabolism and is expressed at high levels in the liver
[5–7]. PPAR-γ, which is most abundant in adipose tissues,
modulates the expression of the genes involved in lipogenesis
and also of the adipokine gene [5, 8, 9]. Furthermore, PPAR-
γ up-regulates adiponectin gene expression in the white
adipose tissues [10]. Increased level of adiponectin enhances
insulin sensitivity by increasing the fat oxidation, resulting
in reduced levels of circulating fatty acids and intracellular
triacylglycerol content in the liver and skeletal muscle [11].
Recently, it was suggested that a dual activation of both
PPAR-α in the liver and PPAR-γ in the adipose tissue are
important for the improvement of the obesity-associated
hyperlipidemia and diabetes [12–14]. Therefore, finding a
food source or a nutrient capable of activating the functions
of both PPAR-α and PPAR-γ would be very desirable for the
treatment and prevention of diseases associated with obesity.
The glycemic index (GI), originally described by Jenkins et
al., is a ranking of carbohydrates based on their immediate
effects on blood glucose levels [15]. Several studies recently
reported that low GI diets improved both glycemic control
and blood lipid profiles [16, 17]. Furthermore, Pawlak et al.
suggested that low GI diet protects β cell expansion and
dysfunction [18]. We previously reported that the MHN-01
(Inslow), which was developed as a low GI liquid formula,
containing palatinose and oleic acid, suppressed post-
prandial hyperglycemia, and reduced hepatic and visceral
fat accumulation better than other commercially available
conventional standard formulas (SF), despite the daily food
intake remaining the same for long-term period in both
groups [19]. However, the detail mechanism of anti-obesity
effect on rat fed Inslow is not clear.
In this study, to elucidate the mechanism of Inslow-
mediated anti-obesity effect, we compared the expression of
several glucose and lipid metabolism-related genes in Inslow-
fed Sprague-Dawley rats with those of the SF-fed rats.
Materials ands Methods
Animals and diets
All protocols for animal use and euthanasia were reviewed
and approved by the Animal Care Committee of the University
of Tokushima and were in accordance with National
Institute of Health guidelines. Sprague-Dawley 19-week-old
male rats obtained from SLC (Shizuoka, Japan) were used
for the experiment. All rats were maintained under a 12 hr
light-dark cycle (lights on from 08:00 to 20:00). They were
fed a standard chow MF (Oriental Yeast Co., Tokyo, Japan)
and water ad libitum for 1 week. After the rats were allowed
to fast for 24 hours, blood samples were collected under
nonanesthesia from the tail vein for the measurement of
plasma glucose and insulin, and under diethyl ether anesthesia
from the left jugular vein for the measurement of plasma
triacyglycerol, free fatty acids (FFAs) and total cholesterol.
Blood glucose was measured by the glucose oxidase method
using Accu-Chek (Roche Diagnostics, Tokyo, Japan). Plasma
insulin level (IRI) was measured with a commercially available
enzyme-linked immunosorbent assay (ELISA) kit (Morinaga,
Yokohama, Japan). Plasma triacyglycerol and FFAs level
were measured using the triacyglycerol and NEFA kit
(Wako, Osaka, Japan).
After the acclimatization period, rats were divided into
two groups: spray-dried Inslow powder fed-rats and spray-
dried SF powder fed-rats, as reported previously [19]
(Table 1). Each group was administered a given diet
(80 kcal/day) with pair feeding condition and water ad
libitum for 8 weeks. Food intake was measured daily and the
body weight was measured weekly during the experimental
period.
Preparation of organs and determination of triacylglycerol
content of liver
All rats on experimental diets were sacrificed after 8
weeks for histological preparations, or to extract total RNA.
The organs were removed and weighed. After weighing, liver
and epididymal fat were immediately frozen in liquid nitrogen
and stored at −80°C until they were used for total RNA
extraction and triacylglycerol content measurement. Total lipid
was extracted from the liver tissues by the method of Folch
et al. as previously described using 2:1 (v/v) chloroform–
methanol [20]. The lipid concentration was determined by
using the triacyglycerol KIT (Wako, Osaka, Japan).
Table 1. Composition of experimental diets
SF Inslow
Energy balance
Protein (%) 16.0 20.0
Fat (%) 25.0 29.7
Carbohydrate (%) 59.0 50.3
Fatty acid composition include
Palmitic acid (%) 6.0 5.8
Stearic acid (%) 3.0 3.7
Oleic acid (%) 45.0 68.5
Linoleic acid (%) 32.0 12.6
α-linolenic acid (%) 8.0 4.2
Other fatty acid (%) 6.0 5.2
Carbohydrate composition include
Palatinose (%) 55.7
Branched dextrin (%) 23.9
Xylitol (%) 5.3
Dextrin (%) 97.2
Sucrose (%) 2.8
Other carbohydrate (%) 15.1
SF: standard formulaK. Matsuo et al.
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Histological analysis of pancreas, adipose and hepatic tissues
and determination of islet and adipocyte sizes
Freshly isolated pancreas, liver and mesenteric fat were fixed
in formaldehyde, dehydrated with increasing concentrations
of ethanol (the final step in 100% ethanol), and embedded in
paraffin. All tissues were cut into 5 µm sections, the sections
were mounted on SuperFrost® slide glasses (Matsunami Glass
Ind., Ltd., Osaka, Japan) and were stained with hematoxylin
and eosin (H&E). To measure the sizes of the islets and
adipocyte, images were captured with a Nikon DXM1200
digital camera and analyzed using Image-Pro Plus 6.0
software (Media Cybernetics, Silver Springs, MD).
RNA extraction and real-time quantitative PCR
The tissue was homogenized in ISOGEN (Nippon Gene
Inc, Tokyo, Japan) with a Polytron tissue homogenizer. Total
RNA was extracted with chloroform, precipitated with
isopropanol, washed with 75% (v/v) ethanol, dissolved in
diethyl pyrocarbonate (DEPC) water. The RNA concentration
was determined by measuring the absorbance at 260 nm.
For cDNA synthesis, 5 µg of total RNA was used as
template. Briefly, the RNA was mixed with 3 µl of random
primers (50 ng/µl) and DEPC-treated water to a final
volume of 25 µl, incubated at 70°C for 10 min, followed by
incubation on ice for 10 min. Then 1 µl of M-MLV-RT (200
units/µl), 10 µl of 5x first strand synthesis buffer, 10 µl of
2.5 mM dNTP, 5 µl of 0.1 mM DTT and 2 µl of DEPC-
treated water was added to the RNA/primer mix and
incubated at 42°C for 1 hr. The reaction was stopped by heat
in activation at 95°C for 2 min and rapidly cooled on ice.
The cDNA was stored immediately at −20°C.
Real-time quantitative PCR was performed in a fluo-
rescence temperature cycler (LightCyclerTM, Roche Molecular
Biochemicals, Mannheim, Germany) according to the
manufacturer’s instructions. The 20 µl amplification mixture
contained 1 µl of cDNA, 0.8 µl of plus 25 mM MgCl2, 1 µl
of each primer, 10 µl of 2 × QuantiTectTM SYBER® Green
PCR Master Mix (QIAGEN, Tokyo, Japan) and 6.2 µl
of dH2O. After 15 min preincubation at 95°C, the PCR
amplification was performed for 50 cycles using the
following cycling conditions: 10 sec denaturation at 95°C,
15 sec annealing at 60°C, and 15 sec extension at 72°C.
Primers were designed using the manufacturer’s software
and the sequences available in the GenBankTM database.
Table 2 shows the sequences of the gene specific PCR
primers. The relative expression levels of the mRNAs of
the target genes were normalized using the β-actin internal
standard.
Statistical analysis
Data are expressed as mean ± S.E. The statistical signifi-
cance of the differences in mean values between the Inslow
and SF groups were assessed by Student’s t  test. All
statistical analyses were performed using StatView software
(Windows, version 5.0).
Table 2. Primers sets for real-time PCR analysis
GenBank 
accession no.
Forward 5' → 3' Reverse 5' → 3'
Product 
length (bp)
PPAR-α M88529 tgtatgaagccatcttcacg ggcattgaacttcatagcga 163
PPAR-γ AF156665 tcaaaccctttaccacggtt caggctctactttgatcgca 147
SREBP1c AF286470 ggagccatggattgcacattt tccttcgaaggtctctcctc 190
CPT-1 NM-031559 ggtgggccacaaattacgtg cagcatctccatggcgtagt 104
DCI NM-017306 tccgaggtgtcatcctcact tgcacagccttccagtactc 115
ACO J02752 atggcagtccggagaataccc cctcataacgctggcttcgagt 114
FAS M76767 tgggcccagcttcttagcc ggaacagcgcagtaccgtaga 104
Acrp30 NM-144744 ggaaacttgtgcaaggttgga ggtcacccttaggaccaaga 140
TNF-α NM-012675 atggatctcaaagacaacca tcctggtatgaaatggcaaa 143
UCP-2 NM-019354 tctcccaatgttgcccgaaa gggaggtcgtctgtcatgag 107
GK J04218 gtgaggcacgaagacctaga ctgtgtcgttcaccattgcc 160
L-PK L37333 ctgccttctggatatcgact gagtcgtgcaatgttcatcc 133
G6Pase M11709 cctccaagtgaattacgaag cagtctcttgaatgtggaac 116
PEPCK AH007109 agacaaatccgaacgccatt catcctgtggtctccactct 162
β-actin NM-031144 gtcccagtatgcctctggtcgtac ccacgctcggtcaggatcttcatg 171
PPAR, peroxisome proliferator activated receptor; SREBP1c, sterol response element binding protein 1c; CPT-1,
carnitine palmitoyltransferase 1; DCI, 3-2 trans enoyl-coA isomerase; ACO, acyl-CoA oxidase; FAS, fatty acid synthase;
Acrp30, adiponectin; TNF-α, tumor necrosis factor-α; UCP-2, uncoupling protein-2; GK, glucokinase; L-PK, liver-type
pyruvate kinase; G6Pase, glucose 6-phosphatase; PEPCK, phosphoenolpyrvate carboxykinase.Palatinose-Base Diet Prevented Obesity via PPAR
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Results
Effects of Inslow on glucose and lipid metabolism
Table 3 shows the metabolic parameters after the ingestion
of Inslow or SF for 8 weeks. In both groups, there was no
difference in average food intake. However, the average
body weight gain in the Inslow group was significantly
lower than that in the SF group (p<0.05). Furthermore, the
average IRI level was significantly lower in the Inslow
group than in the SF group (p<0.01) although the average
fasting blood glucose levels in both groups were not
different. In addition, the average plasma triacylglycerol
level in the Inslow-fed rats was significantly lower than that
in the SF-fed rats (p<0.01), whereas the average FFAs and
total cholesterol levels were comparable between the two
groups.
Histological analysis of the pancreas 
Because the IRI level was significantly lower in the Inslow
group, we histologically analyzed the size of the islets in
Inslow and SF groups. Representative results obtained from
the Inslow and SF groups are shown in Fig. 1 A and B,
respectively. As shown, the average area of islets in the
Inslow group was approximately one-half of that in the SF
group (compare Fig. 1 A and B; p<0.05). Interestingly,
smaller islet size may explain why the IRI level in the Inslow
group was lower than that in the SF group, as documented in
Table 3.
Effects of Inslow administration on the expression of hepatic
glucose and lipid metabolism genes
Fig. 2A shows hematoxylin and eosin stained liver tissues
from the Inslow and SF groups. As shown, Inslow group
contains less lipid accumulation than the SF group. Consistent
with this observation, we found that the hepatic triacyl-
glycerol level was significantly lower in the Inslow group
than the SF group (Fig. 2B; p<0.05). Next, we performed
real-time PCR analysis of hepatic samples to investigate the
expression profiles of genes involved in the glucose and
lipid metabolism. There were no differences in the mRNA
levels of the hepatic glycolytic genes (such as glucokinase
and pyruvate kinase), and hepatic gluconeogenic genes (such
as glucose 6-phosphatase (G6Pase) and phosphoenolpyrvate
carboxykinase (PEPCK)) between the Inslow and SF groups
(data not shown). In contrast, expression level of the PPAR-
α mRNA, a gene involved in the lipid metabolism, was
significantly higher in the Inslow group compared with that in
the SF group (Fig. 2C: p<0.01), although the expression level
of the sterol response element binding protein 1c (SREBP1c)
gene, another gene involved in lipid metabolism, showed no
difference between these two groups (data not shown).
Expressions of ACO (Fig. 2C), CPT-1 (Fig. 2C) and DCI
(data not shown) genes, which are involved in lipid
metabolism and are known to be up-regulated by PPAR-α,
were significantly higher in the Inslow group than in the SF
group (p<0.05, p<0.05 and p<0.01, respectively). We have
Table 3. Effects of SF and Inslow diets on food intake, body
weight gain and plasma parameter levels in SD rats
SF Inslow
Food intake 
(kcal/day)
73.4 ± 2.6 72.6 ± 4.5
Body weight gain 
(g/8wks)
79.8 ± 15.0 33.7 ± 10.0 *
Glucose (mmol/l) 4.54 ± 0.63 4.23 ± 0.41
Insulin (pmol/l) 1171.00 ± 81.33 755.33 ± 41.67 **
Free fatty acid 
(mEq/l)
0.62 ± 0.02 0.58 ± 0.06
Total-cholesterol 
(mmol/l)
1.98 ± 0.13 2.20 ± 0.14
Triacylglycerol 
(mmol/l)
1.23 ± 0.13 0.57 ± 0.05 **
SF:standard formula. Data are presented as mean ± SE. *: p<0.05,
vs SF, **: p<0.01, vs SF.
Fig. 1.  Effects of SF and Inslow diets on pancreas. A) Hematoxylin and eosin staining of the pancreas. Original magnification, ×200.
Scale bars indicate 100 µm. B) Mean islet size. Values are expressed as mean ± SE (n =5 ) .  * p<0.05 vs SF.K. Matsuo et al.
J. Clin. Biochem. Nutr.
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also found that the expression level of the FAS mRNA was
slightly lower (data not shown) and the expression level of
the UCP-2 mRNA was significantly higher (Fig. 2C,
p<0.05) in the Inslow group as compared to those in the SF
group.
Effects of Inslow administration on the expression of adipocyte
lipid metabolism genes
As shown in Fig. 3A, the mesenteric, epididymal and retro-
peritoneal fat masses in the Inslow group were significantly
lower than those in the SF group (p<0.0001, p<0.05 and
p<0.001, respectively). The average sizes of the adipocytes
in the Inslow group were significantly smaller than those
in the SF group in mesenteric fat (Fig. 3B); the reduced adipo-
cyte size might explain the decreased abdominal fat mass.
Fig. 3C shows the expression of several lipid metabolism
associated genes in Inslow and SF adipose tissues. Expression
of the PPAR-γ, UCP-2, adiponectin mRNAs in the epididymal
fat of the Inslow group were higher in the Inslow than in the
SF group. The expression of the CPT-1 and DCI mRNAs in
the Inslow group were also higher than those in the SF group
(data not shown). In contrast, expression of the TNF-α
mRNA in the Inslow group was lower than that in the SF
group (Fig. 3C).
Discussion
In this study, we have observed that even though there
was no significant difference in the amount of food intake
between the Inslow and SF groups, the Inslow group showed
less body weight gain in 8 weeks than the SF group. This
significant decrease in the body weight gain of the Inslow-
fed rats can be attributed to the effectively small amount of
plasma insulin levels in these animals, causing suppression
of postprandial hyperglycemia described in our previous
report [19]. High concentration of glucose was shown to
induce β-cell apoptosis in cultured human and rodent islets
[21, 22]. It was also suggested that suppression of early
insulin secretion controls additional over secretion, and thus,
represses the possibility of pancreatic exhaustion. Pawlak et
al. [18] reported that animals fed a high-GI diet tended to
have a larger β-cell mass compared to those fed a low-GI
diet. Results shown in this study also suggested that Inslow
feeding protected islets from hypertrophic change. Hyper-
glycemia was shown to lower β-cell insulin content as a result
of chronic overstimulation [23]. Together, these data suggest
that Inslow might reduce the burden on the endocrine
pancreas by reducing postprandial plasma glucose and
produce insulin–sparing effect. Consequently, the insulin-
sparing might prevent obesity.
Increased levels of hepatic PPAR-α, β-oxidation enzymes
and UCP-2 mRNAs might explain the lower plasma and
Fig. 2.  Effects of SF and Inslow on lipid metabolism in liver. A) Hematoxylin and eosin staining of the liver. Original magnification,
×200. Scale bars indicate 100 µm. B) Hepatic triacylglycerol content. C) Hepatic gene expression. The gene expression level
was expressed relative to the SF group (=100%) after normalization using the β-actin gene expression level. Values are
expressed as mean ± SE (n =5 ) .  * p<0.05, **p<0.01 vs SF.Palatinose-Base Diet Prevented Obesity via PPAR
Vol. 40, No. 3, 2007
239
hepatic triacylglycerol levels in the Inslow group. The
liver plays a central role in whole-body glucose and lipid
homeostasis, and the hepatic regulation of the expression
of the genes involved in fat oxidation is dependent on
functional PPAR-α [5, 24]. PPAR-α is the molecular target
for the hypolipidemic fibrate drugs, such as clofibrate,
fenofibrate and benzafibrate, which are used for the
treatment of dyslipidemia [7, 25, 26]. It is suggested that the
role of UCP-2 is to eliminate excess energy, and to reduce
free radical formation within the cell. In obesity-resistant
strain mice, UCP-2 mRNA levels significantly increased in
response to a high-fat diet [27]. Induction of UCP-2 may
reduce reactive oxygen species (ROS) [28–30]. Furthermore,
it has been shown that the level of plasma thiobarbituric
acid-reactive substance, a marker of lipid peroxidation, is
inversely proportional to the hepatic PPAR-α mRNA levels
[31]. Therefore, we suggest that Inslow, like fibrate drugs,
exerts hypolipidemic effect, controls energy expenditure and
plays a protective role against formation of ROS.
In the adipose tissue, expression of the PPAR-γ and
adiponectine genes were increased in the Inslow group as
compared to those in the SF group. The PPAR-γ is a master
regulator of adipocyte differentiation, and controls expressions
of various kinds of adipocyte specific genes [5]. Pharma-
cologial activators of PPAR-γ, such as thiazolidinedione
(TZD), significantly improve insulin sensitivity in type 2
diabetes [32, 33]. Okuno et al. [34] previously reported that
in obese rats TZD did not change the total weight of the
white adipose tissues, but increased the number of small
adipocytes. Our results show that Inslow decreased the
abdominal fat mass and increased the number of small
adipocytes. Furthermore, Inslow enhanced the β-oxidation
enzyme gene expression in the adipose tissue. Therefore, we
suggest that Inslow promotes insulin–sparing effect, increases
the number of small adipocyte, and increases the expression
of the PPAR-γ mRNA to stimulate the fatty acid utilization.
Adiponectin is an adipocyte-derived hormone that plays
a role in insulin sensitivity and energy homeostasis [11].
Previous reports showed that both heterozygous PPAR-γ
deficiency [35] and administration of PPAR-γ agonist [36]
up-regulated the adiponectin mRNA level in the small size
adipocytes. Increased plasma adiponectin level improves
insulin action accompanied by enhanced fatty acid oxidation
in liver and muscle [10, 37]. Furthermore, recent reports
showed that adiponectin enhanced AMP-activated protein
kinase (AMPK) phosphorylation, which resulted in increased
fatty acid oxidation [38]. Therefore, increased adiponectin
mRNA expression in the Inslow administered group might
Fig. 3.  Effects of SF and Inslow diets on adiposity in white adipose tissue (WAT). A) Weight of mesenteric, epididymal, retroperitoneal
and total abdominal fat. B) Histological analysis (top), and cell size distribution (bottom) of mesenteric WAT. Bar indicates
100 µm. C) Adipose gene expression. The gene expression level was expressed relative to the SF group (=100%) after
normalization using the β-actin gene expression level. Values are expressed as mean ± SE (n =5 ) .  * p<0.05, **p<0.01,
#p<0.001, ##p<0.0001 vs SF.K. Matsuo et al.
J. Clin. Biochem. Nutr.
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be attributable to the activation of the adiponectin promoter
via the PPAR-γ pathway, which might consequently enhance
the fatty acid oxidation in liver.
In conclusion, our findings suggested that Inslow, which
contains palatinose, was an effective functional food for the
prevention and treatment of obesity, diabetes and metabolic
syndrome because it can maintain the glucose and lipid
homeostasis by regulating the expression of the hepatic
PPAR-α and adipose PPAR-γ genes.
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